292 related articles for article (PubMed ID: 26392111)
1. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
De Iuliis F; Salerno G; Giuffrida A; Milana B; Taglieri L; Rubinacci G; Giantulli S; Terella F; Silvestri I; Scarpa S
Tumour Biol; 2016 Feb; 37(2):2603-11. PubMed ID: 26392111
[TBL] [Abstract][Full Text] [Related]
2. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells.
De Iuliis F; Taglieri L; Salerno G; Giuffrida A; Milana B; Giantulli S; Carradori S; Silvestri I; Scarpa S
Invest New Drugs; 2016 Aug; 34(4):399-406. PubMed ID: 26994617
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome changes induced by docetaxel in human mammary cell lines expressing different levels of ERBB2.
Dos Santos ML; Gimenes KP; Silva WA; Nagai MA
Int J Mol Med; 2009 Jun; 23(6):733-43. PubMed ID: 19424599
[TBL] [Abstract][Full Text] [Related]
4. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.
Singel SM; Cornelius C; Batten K; Fasciani G; Wright WE; Lum L; Shay JW
Clin Cancer Res; 2013 Apr; 19(8):2061-70. PubMed ID: 23479679
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance.
Nestal de Moraes G; Delbue D; Silva KL; Robaina MC; Khongkow P; Gomes AR; Zona S; Crocamo S; Mencalha AL; Magalhães LM; Lam EW; Maia RC
Cell Signal; 2015 Dec; 27(12):2496-505. PubMed ID: 26404623
[TBL] [Abstract][Full Text] [Related]
8. STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers.
Kim JS; Kim HA; Seong MK; Seol H; Oh JS; Kim EK; Chang JW; Hwang SG; Noh WC
Oncotarget; 2016 Feb; 7(6):7055-65. PubMed ID: 26755645
[TBL] [Abstract][Full Text] [Related]
9. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
10. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
12. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Wang S; Huang X; Lee CK; Liu B
Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
[TBL] [Abstract][Full Text] [Related]
13. miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression.
Yao YS; Qiu WS; Yao RY; Zhang Q; Zhuang LK; Zhou F; Sun LB; Yue L
Oncol Rep; 2015 May; 33(5):2504-12. PubMed ID: 25813250
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of phosphorylation-defective survivin on radiation response in estrogen receptor-positive and -negative breast cancer.
Debeb BG; Smith DL; Li L; Larson R; Xu W; Woodward WA
PLoS One; 2015; 10(3):e0120719. PubMed ID: 25763854
[TBL] [Abstract][Full Text] [Related]
16. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
17. Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.
Jin Y; Hu W; Liu T; Rana U; Aguilera-Barrantes I; Kong A; Kumar SN; Wang B; Gao P; Wang X; Duan Y; Shi A; Song D; Yang M; Li S; Han B; Zhao G; Fan Z; Miao QR
Cancer Lett; 2018 Apr; 419():233-244. PubMed ID: 29373839
[TBL] [Abstract][Full Text] [Related]
18. Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint.
Badtke MM; Jambal P; Dye WW; Spillman MA; Post MD; Horwitz KB; Jacobsen BM
Breast Cancer Res Treat; 2012 Jan; 131(1):75-87. PubMed ID: 21340479
[TBL] [Abstract][Full Text] [Related]
19. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of mild hyperthermia plus docetaxel therapy on ER(+/-) breast cancer cells and action mechanisms.
Lv F; Yu Y; Zhang B; Liang D; Li ZM; You W
J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):870-876. PubMed ID: 24337851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
